House passes AHA-supported bills to promote generic drug competition
The House of Representative today passed two AHA-supported bills to promote generic and biosimilar competition in the prescription drug market. The Orange Book Transparency Act (H.R. 1503) and Purple Book Continuity Act (H.R. 1520) would increase the accuracy and transparency of the two databases that guide development decisions for generic and biosimilar manufacturers.
Related News Articles
Headline
The House Energy and Commerce Committee held a markup April 29 where it advanced the AHA-supported SUPPORT Act (H.R. 2483). The legislation would reauthorize…
Perspective
One year ago, a nurse at Children’s Hospital Colorado went above and beyond in a way that a very young patient and her family will never forget. Kayla…
Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription…
Headline
The Department of Commerce yesterday released notices announcing national security investigations on imports of pharmaceuticals, pharmaceutical ingredients and…
Headline
Achieving operational and survey readiness on day one is an issue that many health care facilities professionals continue to grapple with, according to…
Perspective
Congressional lawmakers are heading home for a two-week district work period after both the Senate and House passed a revised budget resolution for fiscal year…